CRIS Current Research Information System

ZINZANI, PIER LUIGI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 33.223
NA - Nord America 29.736
EU - Europa 21.961
SA - Sud America 2.384
AF - Africa 1.409
OC - Oceania 71
Continente sconosciuto - Info sul continente non disponibili 23
Totale 88.807
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 29.333
SG - Singapore 9.084
CN - Cina 8.909
VN - Vietnam 8.073
GB - Regno Unito 4.509
IT - Italia 3.355
DE - Germania 2.971
NL - Olanda 2.574
SE - Svezia 2.254
HK - Hong Kong 2.230
BR - Brasile 1.735
FR - Francia 1.506
IN - India 1.446
KR - Corea 1.196
RU - Federazione Russa 1.180
UA - Ucraina 811
IE - Irlanda 692
JP - Giappone 633
FI - Finlandia 608
ZA - Sudafrica 468
CI - Costa d'Avorio 316
EE - Estonia 309
AR - Argentina 277
ID - Indonesia 215
TG - Togo 203
CH - Svizzera 190
CA - Canada 184
PH - Filippine 172
AT - Austria 164
BD - Bangladesh 156
JO - Giordania 146
PL - Polonia 145
MX - Messico 138
TH - Thailandia 138
HR - Croazia 132
SC - Seychelles 120
IQ - Iraq 114
TR - Turchia 101
ES - Italia 100
EC - Ecuador 97
BG - Bulgaria 93
BE - Belgio 88
TW - Taiwan 88
NG - Nigeria 83
PK - Pakistan 75
SA - Arabia Saudita 72
CL - Cile 63
IR - Iran 58
AU - Australia 56
CO - Colombia 56
GR - Grecia 55
UZ - Uzbekistan 47
VE - Venezuela 47
EG - Egitto 45
PY - Paraguay 43
LB - Libano 36
MY - Malesia 36
MA - Marocco 32
LT - Lituania 31
PE - Perù 31
RO - Romania 29
IL - Israele 26
DZ - Algeria 25
CZ - Repubblica Ceca 23
TN - Tunisia 23
AL - Albania 22
KE - Kenya 22
AE - Emirati Arabi Uniti 21
LU - Lussemburgo 21
AZ - Azerbaigian 19
KZ - Kazakistan 19
DO - Repubblica Dominicana 18
EU - Europa 18
BO - Bolivia 16
OM - Oman 16
RS - Serbia 16
UY - Uruguay 16
ET - Etiopia 15
NP - Nepal 15
DK - Danimarca 13
HU - Ungheria 12
CR - Costa Rica 11
NZ - Nuova Zelanda 11
PT - Portogallo 11
PA - Panama 10
BY - Bielorussia 8
GH - Ghana 8
JM - Giamaica 8
PR - Porto Rico 8
GE - Georgia 7
KG - Kirghizistan 7
LY - Libia 7
SK - Slovacchia (Repubblica Slovacca) 7
SN - Senegal 7
AM - Armenia 6
AO - Angola 6
BH - Bahrain 6
KW - Kuwait 6
MM - Myanmar 6
QA - Qatar 6
Totale 88.670
Salva come PNG Salva come JPEG
Città #
Singapore 6.261
Southend 3.817
Fairfield 3.121
Ashburn 2.963
Hefei 2.545
Hong Kong 2.106
Ho Chi Minh City 1.877
San Jose 1.833
Chandler 1.648
Hanoi 1.528
Woodbridge 1.504
Houston 1.474
Seattle 1.377
Wilmington 1.367
Eygelshoven 1.296
Cambridge 1.106
Princeton 1.090
Seoul 1.086
Ann Arbor 1.038
Santa Clara 1.038
Beijing 803
Boardman 800
Dong Ket 762
Lauterbourg 728
Dublin 692
Kerkrade 666
Bologna 614
Frankfurt am Main 543
Tokyo 542
Los Angeles 494
Helsinki 465
Nanjing 422
Jacksonville 417
Westminster 412
Milan 359
New York 350
Berlin 341
Padova 337
Abidjan 316
Dallas 297
Buffalo 289
Council Bluffs 281
Da Nang 269
Haiphong 247
Jinan 236
Bengaluru 234
Redondo Beach 211
Lomé 202
Shenyang 195
San Diego 194
Saint Petersburg 192
São Paulo 186
Changsha 173
Guangzhou 162
Nuremberg 148
Amman 144
Turin 142
Hebei 134
Shanghai 132
Nanchang 131
Tianjin 130
Chicago 128
Bern 127
London 125
Jakarta 124
Rome 124
Zhengzhou 120
Bremen 119
Munich 119
Lappeenranta 111
Hangzhou 100
Warsaw 96
Mülheim 94
Redmond 93
Redwood City 93
Des Moines 92
Jiaxing 90
Biên Hòa 89
The Dalles 89
Johannesburg 85
Sofia 84
Amsterdam 83
Hải Dương 82
Hyderabad 81
Falls Church 80
Olalla 78
Florence 77
Dearborn 76
Vienna 75
Yubileyny 75
Falkenstein 72
Toronto 72
Brussels 71
Phoenix 71
Norwalk 68
Rio de Janeiro 68
Taizhou 68
Thái Nguyên 67
Can Tho 66
Tongling 66
Totale 57.965
Salva come PNG Salva come JPEG
Nome #
90-yttrium-ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high-risk follicular lymphoma: updated long-term results after a median follow-up of 7 years 2.841
Consensus conference on the management of tumor lysis syndrome. 440
BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience 427
Overview of alemtuzumab therapy for the treatment of T-cell lymphomas. 363
18F-FDG PET early after radiotherapy in lymphoma patients. 315
Impact of a newly established expert clinical pharmacological advice program based on TDM results in tailoring antimicrobial therapies hospital-wide in a tertiary university hospital: findings after the first-year of implementation 310
CAR+ extracellular vesicles predict ICANS in patients with B cell lymphomas treated with CD19-directed CAR T cells 295
VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly. 283
Genomic Profiling of Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System Suggests Novel Potential Therapeutic Targets 278
Biology and treatment of follicular lymphoma. 277
B cell chronic lymphocytic leukaemia/small lymphocytic lymphoma: role of ZAP70 determination on bone marrow biopsy specimens 277
Gastric MALT Lymphoma in a Sleeve Gastrectomy Specimen: Case Report and Literature Review 275
[18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study. 266
Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortium 265
The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study 253
A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma. 251
CDKN1B/p27 expression in peripheral T cell lymphoma not otherwise specified. 248
Prevention of large-scale implementation of unnecessary and expensive predictive tests in Hodgkin's lymphoma – Authors' reply 248
Effectiveness of Fludarabine, Idarubicin and Cyclophosphade (FLUIC) Combination Regimen for Young Patients with Untreated Non-Follicular Low-Grade Non-Hodgkin’s Lymphoma. 246
Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients. 244
A case of pityriasis lichenoides et varioliformis acuta developed after first dose of Oxford-AstraZeneca COVID-19 vaccine 243
A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. 241
18 F-FDG PET in malignant lymphoma: significance of positive findings 238
High efficacy of the MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis, a 20 year experience 237
Allotransplant in relapsed or refractory aggressive T-cell lymphomas: retrospective monocentric analysis of 14 patients 235
Intracranial pressure management in fulminant cerebral oedema after CAR T-cell therapy: Not all is lost! 233
Design of New Personalized Therapeutic Approaches for Diffuse Large B-Cell Lymphoma through Gut Microbiome Profiling 232
A phase 2 trial of fludarabine and mitoxantrone chemoterapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma 232
Is it really possible to cure hairy cell leukemia patients only with frontline therapy? 231
Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients. 228
T-Cell Lymphomas in South America and Europe 223
(90) Y-ibritumomab tiuxetan in patients with extra-nodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) - The Zeno Study 223
The Berlin-Frankfurt-Münster protocol for the upfront treatment of aggressive lymphomas: The Bologna experience 222
Peripheral blood cellular profile at pre-lymphodepletion is associated with {CD}19-targeted {CAR}-T cell-associated neurotoxicity 221
Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma. 221
Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. 218
Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up. 218
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 217
Value of oxaliplatin treatment in heavily pretreated patients with non-Hodgkin's lymphoma. 216
Dissection of DLBCL Microenvironment Provides a Gene Expression-Based Predictor of Survival Applicable to Formalin-Fixed Paraffin-Embedded Tissue 216
An isolated penile mass in a young adult turned out to be a primary marginal zone lymphoma of the penis. A case report and a review of literature. 215
18F-FDG PET in mucosa-associated lymphoid tissue (MALT) lymphoma. 214
Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study 214
Management of chronic lymphocytic leukemia: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. 213
Siltuximab in relapsed/refractory multicentric Castleman disease: Experience of the Italian NPP program 213
Detection of Brain-Derived Cell-Free DNA in Plasma 212
A patient with plasmablastic lymphoma achieving long-term complete remission after thalidomide-dexamethasone induction and double autologous stem cell transplantation: a case report 212
High-dose therapy with autologous transplantation for aggressive non-Hodgkin's lymphoma: the Bologna experience 210
RALE051: a novel established cell line of sporadic Burkitt lymphoma 209
Case report: Senescence as mechanism of resistance to Pembrolizumab in a Lymphoma patient who failed CD19-Targeted CAR-T cell therapy 208
Expression of CD52 in peripheral T-cell lymphoma. 208
Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma. 207
Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma 207
Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays. 206
Bendamustine-rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients 205
Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. 202
Lymphoma: diagnosis, staging, natural history, and treatment strategies. 201
Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. 201
Interim positron emission tomography response-adapted therapy in advanced-stage hodgkin lymphoma: Final results of the phase II part of the HD0801 study 201
Efficacy and Safety of Frontline Single‐Agent Rituximab in Extranodal Marginal Zone Lymphoma 199
Long-term responders after Brentuximab vedotin: Single-center experience on relapsed and refractory hodgkin lymphoma and anaplastic large cell lymphoma patients 199
Role of [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma 199
Primary non-hodgkin’s lymphoma of bone: treatment and analysis of prognostic factors for stage I and stage II 199
Metabolic profile evolution in relapsed/refractory B-cell non-Hodgkin lymphoma patients treated with CD19 chimeric antigen receptor T-cell therapy and implications in clinical outcome 199
A 3-gene signature based on MYC, BCL-2 and NFKBIA improves risk stratification in diffuse large B-cell lymphoma 197
Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome. 196
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma 194
The treatment of primary mediastinal large B-cell lymphoma: A two decades monocentric experience with 98 patients 194
The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients 194
Economic evaluation of anti-CD19 CAR T-cell pathway for large B-cell lymphomas in the real-life setting: the experience of an Italian hub center in the first three years of activity 193
Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients. 193
CAR t-cell therapy in BOlogNa–NEUrotoxicity TReatment and Assessment in Lymphoma (CARBON–NEUTRAL): proposed protocol and results from an Italian study 192
Brentuximab vedotin followed by ABVD +/- radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II study 192
Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma. 191
CD30 expression in peripheral T-cell lymphomas 191
Discordant response to chemotherapy: An unusual pattern of fluoro-deoxy-D-glucose uptake in heavily pre-treated lymphoma patients 190
Phase II trial of temozolomide in patients with pretreated cutaneous T-cell lymphoma. 189
Role of interferon-alpha administration after 2-deoxycoformycin in the treatment of hairy cell leukemia patients. 189
Molecular Profiling Improves Classification and Prognostication of Nodal Peripheral T-Cell Lymphomas: Results of a Phase III Diagnostic Accuracy Study 189
Platelet-derived growth factor alpha mediates the proliferation of peripheral T-cell lymphoma cells via an autocrine regulatory pathway. 189
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 188
PD-1 blockade as bridge to allogenic stem cell transplantation in relapsed/refractory Hodgkin lymphoma patients: a retrospective single center case series 188
Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding 187
Erythrophagocytosis by neoplastic cells in a patient with myelodysplastic syndrome 186
Histopathology of B-cell chronic lymphocytic leukemia. 186
Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients. 185
Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma 185
Does Cytokine-Release Syndrome Induced by CAR T-Cell Treatment Have an Impact on the Pharmacokinetics of Meropenem and Piperacillin/Tazobactam in Patients with Hematological Malignancies? Findings from an Observational Case-Control Study 184
The role of mitoxantrone in the treatment of indolent lymphomas. 184
Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. 184
Nodal marginal-zone lymphoma associated with monoclonal light-chain and heavy-chain deposition disease. 183
Consensus conference on the use of 90-yttrium-ibritumomab tiuxetan therapy in clinical practice. A project of the Italian society of hematology. 182
Association of essential thrombocythemia and non-Hodgkin lymphoma: a single-centre experience 182
Hairy Cell Leukemia: Allogeneic Transplantation Could be an Optimal Option in Selected Patients. 182
A multicenter phase II trial (SAKK 36/06) of single-agent Everolimus(RAD001) in patients with relapsed or refractory mantle cell lymphoma. 181
Collection of Hematopoietic Stem Cells after Previous Radioimmunotherapy is Feasible and Does Not Impair Engraftment after Autologous Stem Cell Transplantation in Follicular Lymphoma. 181
Potential pitfalls of 18F-FDG PET in a large series of patients treated for malignant lymphoma: prevalence and scan interpretation. 181
Anaplastic Large Cell Lymphoma: a critical reappraisal 180
Utility of baseline 18FDG PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma 180
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial 180
Totale 24.642
Salva come PNG Salva come JPEG
Categoria #
all - tutte 241.317
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 241.317
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.543 0 0 0 0 0 0 0 0 0 278 317 1.948
2021/20228.269 901 251 567 737 812 444 178 671 307 477 1.593 1.331
2022/20238.447 973 1.102 503 1.028 698 601 280 540 1.390 301 606 425
2023/20242.799 180 449 201 270 223 374 177 180 98 278 218 151
2024/202514.004 430 2.120 1.121 963 1.794 681 1.165 392 347 1.025 1.003 2.963
2025/202635.175 3.055 4.480 3.615 2.872 3.298 3.296 4.539 1.990 5.850 2.180 0 0
Totale 90.656